Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the prostate cancer prevention trial

Siobhan Sutcliffe, Raphael P. Viscidi, Cathee Till, Phyllis J. Goodman, Ashraful M. Hoque, Ann W. Hsing, Ian M. Thompson, Jonathan M. Zenilman, Angelo M. De Marzo, Elizabeth A. Platz

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Since human papillomavirus (HPV) infection was first identified as a risk factor for cervical cancer, several seroepidemiologic and tissue-based studies have investigated HPV in relation to prostate cancer, another common genitourinary malignancy, with mixed results. To further inform this potential association, we conducted a large, prospective investigation of HPV types 16, 18, and 31 in relation to risk of prostate cancer in the Prostate Cancer Prevention Trial. Cases were a sample of men diagnosed with prostate cancer after visit 2 or on their end-of-study biopsy (n = 616). Controls were men not diagnosed with prostate cancer during the trial or on their end-of-study biopsy (n = 616). Controls were frequency matched to cases by age, treatment arm, and family history of prostate cancer. Sera from visit 2 were tested for IgG antibodies against HPV types 16, 18, and 31. No associations were observed for weak or strong HPV-16 [odds ratio (OR), 0.94; 95% confidence interval (95% CI), 0.53-1.64 and OR, 1.07; 95% CI, 077-1.48, respectively], HPV-18 (OR, 0.75; 95% CI, 0.27-2.04 and OR, 0.87; 95% CI, 0.47-1.63, respectively), or HPV-31 seropositivity (OR, 0.76; 95% CI, 0.45-1.28 and OR, 1.15; 95% CI, 0.80-1.64, respectively) and risk of prostate cancer. Considering this finding in the context of the HPV and prostate cancer literature, HPV does not appear to be associated with risk of prostate cancer, at least by mechanisms proposed to date, and using epidemiologic designs and laboratory techniques currently available.

Original languageEnglish (US)
Pages (from-to)614-618
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume19
Issue number2
DOIs
StatePublished - Feb 2010

Fingerprint

Human papillomavirus 31
Human papillomavirus 18
Human papillomavirus 16
Prostatic Neoplasms
Odds Ratio
Confidence Intervals
Biopsy
Papillomavirus Infections
Uterine Cervical Neoplasms

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the prostate cancer prevention trial. / Sutcliffe, Siobhan; Viscidi, Raphael P.; Till, Cathee; Goodman, Phyllis J.; Hoque, Ashraful M.; Hsing, Ann W.; Thompson, Ian M.; Zenilman, Jonathan M.; De Marzo, Angelo M.; Platz, Elizabeth A.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 19, No. 2, 02.2010, p. 614-618.

Research output: Contribution to journalArticle

Sutcliffe, S, Viscidi, RP, Till, C, Goodman, PJ, Hoque, AM, Hsing, AW, Thompson, IM, Zenilman, JM, De Marzo, AM & Platz, EA 2010, 'Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the prostate cancer prevention trial', Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 2, pp. 614-618. https://doi.org/10.1158/1055-9965.EPI-09-1080
Sutcliffe, Siobhan ; Viscidi, Raphael P. ; Till, Cathee ; Goodman, Phyllis J. ; Hoque, Ashraful M. ; Hsing, Ann W. ; Thompson, Ian M. ; Zenilman, Jonathan M. ; De Marzo, Angelo M. ; Platz, Elizabeth A. / Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the prostate cancer prevention trial. In: Cancer Epidemiology Biomarkers and Prevention. 2010 ; Vol. 19, No. 2. pp. 614-618.
@article{ad80a3a50e2e478fae80bf47f27141ef,
title = "Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the prostate cancer prevention trial",
abstract = "Since human papillomavirus (HPV) infection was first identified as a risk factor for cervical cancer, several seroepidemiologic and tissue-based studies have investigated HPV in relation to prostate cancer, another common genitourinary malignancy, with mixed results. To further inform this potential association, we conducted a large, prospective investigation of HPV types 16, 18, and 31 in relation to risk of prostate cancer in the Prostate Cancer Prevention Trial. Cases were a sample of men diagnosed with prostate cancer after visit 2 or on their end-of-study biopsy (n = 616). Controls were men not diagnosed with prostate cancer during the trial or on their end-of-study biopsy (n = 616). Controls were frequency matched to cases by age, treatment arm, and family history of prostate cancer. Sera from visit 2 were tested for IgG antibodies against HPV types 16, 18, and 31. No associations were observed for weak or strong HPV-16 [odds ratio (OR), 0.94; 95{\%} confidence interval (95{\%} CI), 0.53-1.64 and OR, 1.07; 95{\%} CI, 077-1.48, respectively], HPV-18 (OR, 0.75; 95{\%} CI, 0.27-2.04 and OR, 0.87; 95{\%} CI, 0.47-1.63, respectively), or HPV-31 seropositivity (OR, 0.76; 95{\%} CI, 0.45-1.28 and OR, 1.15; 95{\%} CI, 0.80-1.64, respectively) and risk of prostate cancer. Considering this finding in the context of the HPV and prostate cancer literature, HPV does not appear to be associated with risk of prostate cancer, at least by mechanisms proposed to date, and using epidemiologic designs and laboratory techniques currently available.",
author = "Siobhan Sutcliffe and Viscidi, {Raphael P.} and Cathee Till and Goodman, {Phyllis J.} and Hoque, {Ashraful M.} and Hsing, {Ann W.} and Thompson, {Ian M.} and Zenilman, {Jonathan M.} and {De Marzo}, {Angelo M.} and Platz, {Elizabeth A.}",
year = "2010",
month = "2",
doi = "10.1158/1055-9965.EPI-09-1080",
language = "English (US)",
volume = "19",
pages = "614--618",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the prostate cancer prevention trial

AU - Sutcliffe, Siobhan

AU - Viscidi, Raphael P.

AU - Till, Cathee

AU - Goodman, Phyllis J.

AU - Hoque, Ashraful M.

AU - Hsing, Ann W.

AU - Thompson, Ian M.

AU - Zenilman, Jonathan M.

AU - De Marzo, Angelo M.

AU - Platz, Elizabeth A.

PY - 2010/2

Y1 - 2010/2

N2 - Since human papillomavirus (HPV) infection was first identified as a risk factor for cervical cancer, several seroepidemiologic and tissue-based studies have investigated HPV in relation to prostate cancer, another common genitourinary malignancy, with mixed results. To further inform this potential association, we conducted a large, prospective investigation of HPV types 16, 18, and 31 in relation to risk of prostate cancer in the Prostate Cancer Prevention Trial. Cases were a sample of men diagnosed with prostate cancer after visit 2 or on their end-of-study biopsy (n = 616). Controls were men not diagnosed with prostate cancer during the trial or on their end-of-study biopsy (n = 616). Controls were frequency matched to cases by age, treatment arm, and family history of prostate cancer. Sera from visit 2 were tested for IgG antibodies against HPV types 16, 18, and 31. No associations were observed for weak or strong HPV-16 [odds ratio (OR), 0.94; 95% confidence interval (95% CI), 0.53-1.64 and OR, 1.07; 95% CI, 077-1.48, respectively], HPV-18 (OR, 0.75; 95% CI, 0.27-2.04 and OR, 0.87; 95% CI, 0.47-1.63, respectively), or HPV-31 seropositivity (OR, 0.76; 95% CI, 0.45-1.28 and OR, 1.15; 95% CI, 0.80-1.64, respectively) and risk of prostate cancer. Considering this finding in the context of the HPV and prostate cancer literature, HPV does not appear to be associated with risk of prostate cancer, at least by mechanisms proposed to date, and using epidemiologic designs and laboratory techniques currently available.

AB - Since human papillomavirus (HPV) infection was first identified as a risk factor for cervical cancer, several seroepidemiologic and tissue-based studies have investigated HPV in relation to prostate cancer, another common genitourinary malignancy, with mixed results. To further inform this potential association, we conducted a large, prospective investigation of HPV types 16, 18, and 31 in relation to risk of prostate cancer in the Prostate Cancer Prevention Trial. Cases were a sample of men diagnosed with prostate cancer after visit 2 or on their end-of-study biopsy (n = 616). Controls were men not diagnosed with prostate cancer during the trial or on their end-of-study biopsy (n = 616). Controls were frequency matched to cases by age, treatment arm, and family history of prostate cancer. Sera from visit 2 were tested for IgG antibodies against HPV types 16, 18, and 31. No associations were observed for weak or strong HPV-16 [odds ratio (OR), 0.94; 95% confidence interval (95% CI), 0.53-1.64 and OR, 1.07; 95% CI, 077-1.48, respectively], HPV-18 (OR, 0.75; 95% CI, 0.27-2.04 and OR, 0.87; 95% CI, 0.47-1.63, respectively), or HPV-31 seropositivity (OR, 0.76; 95% CI, 0.45-1.28 and OR, 1.15; 95% CI, 0.80-1.64, respectively) and risk of prostate cancer. Considering this finding in the context of the HPV and prostate cancer literature, HPV does not appear to be associated with risk of prostate cancer, at least by mechanisms proposed to date, and using epidemiologic designs and laboratory techniques currently available.

UR - http://www.scopus.com/inward/record.url?scp=76149119429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76149119429&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-09-1080

DO - 10.1158/1055-9965.EPI-09-1080

M3 - Article

VL - 19

SP - 614

EP - 618

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 2

ER -